EVA is registered trademark of Stern Stewart.
Economic value added or economic profit is the difference between revenues and costs,where costs include not only expenses, but also cost of capital.
Paying user area
Try for free
Allergan PLC pages available for free this week:
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Common Stock Valuation Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Price to FCFE (P/FCFE)
- Selected Financial Data since 2005
- Net Profit Margin since 2005
- Return on Assets (ROA) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Allergan PLC for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Economic Profit
| 12 months ended: | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | |
|---|---|---|---|---|---|---|
| Net operating profit after taxes (NOPAT)1 | ||||||
| Cost of capital2 | ||||||
| Invested capital3 | ||||||
| Economic profit4 | ||||||
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
1 NOPAT. See details »
2 Cost of capital. See details »
3 Invested capital. See details »
4 2019 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= – × =
The financial performance, as measured by economic profit, demonstrates consistent negative values over the five-year period. Net operating profit after taxes (NOPAT) remains negative throughout, contributing significantly to the overall negative economic profit. Invested capital exhibits a declining trend, while the cost of capital fluctuates within a relatively narrow range.
- Net Operating Profit After Taxes (NOPAT)
- NOPAT is negative for each year presented. The largest negative value occurs in 2017, at -US$10,550,503 thousand, representing the poorest operating performance within the observed timeframe. While NOPAT improves slightly in 2018 and 2019, it remains substantially negative. The initial years, 2015 and 2016, show NOPAT of -US$3,502,617 thousand and -US$2,001,620 thousand respectively.
- Cost of Capital
- The cost of capital shows some variability. It begins at 19.70% in 2015, decreases to 19.05% in 2016, and reaches a low of 17.13% in 2017. It then increases to 18.41% in 2018 before rising again to 19.98% in 2019. This fluctuation suggests potential changes in the company’s risk profile or market conditions affecting its funding costs.
- Invested Capital
- Invested capital demonstrates a consistent downward trend throughout the period. Starting at US$127,501,981 thousand in 2015, it decreases to US$80,268,300 thousand by 2019. This reduction in invested capital could be due to asset sales, reduced investment in new projects, or a decrease in working capital requirements. The rate of decline appears to accelerate in the later years.
- Economic Profit
- Economic profit is negative in all observed years, ranging from approximately -US$21 million to -US$28.7 million. The most substantial negative economic profit is recorded in 2015 at -US$28,625,003 thousand. While there is some fluctuation, the values remain consistently negative, indicating that the company is not generating returns exceeding its cost of capital. The negative economic profit mirrors the negative NOPAT and is exacerbated by the substantial invested capital base.
Overall, the analysis reveals a pattern of negative economic profit driven by consistently negative NOPAT and a substantial, though decreasing, invested capital base. The cost of capital remains relatively stable, but does not contribute to improved economic performance. The declining invested capital may indicate strategic shifts or financial constraints.
Net Operating Profit after Taxes (NOPAT)
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
1 Elimination of deferred tax expense. See details »
2 Addition of increase (decrease) in allowance for doubtful accounts.
3 Addition of increase (decrease) in deferred revenue.
4 Addition of increase (decrease) in accrued product warranties.
5 Addition of increase (decrease) in restructuring reserve.
6 Addition of increase (decrease) in equity equivalents to net income (loss) attributable to shareholders.
7 2019 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =
8 2019 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 12.50% =
9 Addition of after taxes interest expense to net income (loss) attributable to shareholders.
10 2019 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 12.50% =
11 Elimination of after taxes investment income.
12 Elimination of discontinued operations.
- Net Income (Loss) Attributable to Shareholders
-
The net income attributable to shareholders shows significant volatility over the observed period. Starting from approximately 3.9 billion US dollars at the end of 2015, it experienced a substantial increase to nearly 15 billion US dollars by the end of 2016. This peak was followed by a sharp reversal into negative territory, with losses amounting to approximately 4.1 billion US dollars in 2017. The negative trend continued in subsequent years, with losses deepening to around 5.1 billion and 5.3 billion US dollars in 2018 and 2019, respectively.
- Net Operating Profit After Taxes (NOPAT)
-
The NOPAT metric also reflects a deteriorating operating performance over the period. It began in 2015 with a negative figure of about 3.5 billion US dollars, improved slightly in 2016 to approximately minus 2 billion US dollars, indicating a reduction in operating losses. However, in 2017, NOPAT deteriorated sharply, reaching a loss exceeding 10.5 billion US dollars. This was followed by some improvement yet continued negative results in 2018 and 2019, with losses of about 5.7 billion and 5.4 billion US dollars, respectively.
- Overall Financial Trends
-
The company’s financial performance exhibits considerable instability over the five-year span. The marked peak in net income in 2016 appears anomalous given the general trend of losses in other years. Both net income and operating profitability suffer from large losses in recent years following the 2016 peak, suggesting potential challenges affecting operational efficiency and profitability after 2016.
The divergence between net income and NOPAT indicates that non-operating factors, such as one-time gains or losses, may have influenced net income, particularly in 2016. The sustained negative operating profit after taxes highlights fundamental operational difficulties that warrant further investigation.
Cash Operating Taxes
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
The data reveals significant fluctuations in the provision (benefit) for income taxes over the five years analyzed. Initially, there is a substantial tax benefit recorded, with the provision showing negative values each year from 2015 through 2018, indicating the company recognized income tax benefits rather than expenses during this period. The magnitude of the benefit peaks in 2017 with an amount exceeding -6.6 million US dollars, suggesting an extraordinary tax gain or adjustment that year. However, in 2019, this trend reverses, and the provision shifts to a positive value of approximately 146 thousand US dollars, reflecting a tax expense rather than a benefit.
In contrast, the cash operating taxes exhibit a more variable and less consistent pattern. The cash taxes paid decreased from about 398 thousand US dollars in 2015 to roughly 295 thousand in 2016 but then surged to approximately 1.24 million in 2017. This rise contrasts with the significant tax benefit recorded in the provision for the same year. A striking observation is seen in 2018 when the cash operating taxes turn negative, indicating a tax refund or credit of nearly 399 thousand US dollars. Following this, the cash taxes return to a positive figure of approximately 897 thousand US dollars in 2019.
Overall, the provision for income taxes and cash operating taxes demonstrate divergent movements during several years, which may indicate timing differences, adjustments, or tax strategy effects on reported versus actual cash tax payments. The large tax benefits recorded in provisions in earlier years, especially 2017, suggest one-time tax events or re-measurements impacting the income statement, while the cash operating taxes reflect the actual tax payments made or refunded, exhibiting a more volatile profile with a notable negative value in 2018.
Invested Capital
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
1 Addition of capitalized operating leases.
2 Elimination of deferred taxes from assets and liabilities. See details »
3 Addition of allowance for doubtful accounts receivable.
4 Addition of deferred revenue.
5 Addition of accrued product warranties.
6 Addition of restructuring reserve.
7 Addition of equity equivalents to shareholders’ equity.
8 Removal of accumulated other comprehensive income.
9 Subtraction of construction in progress.
10 Subtraction of marketable securities and other long-term investments.
The financial data reveals several important trends over the five-year period ending December 31, 2019. The total reported debt and leases exhibit a consistent downward trajectory. Starting from approximately $42.89 billion in 2015, the debt decreases every year, reaching about $23.22 billion by the end of 2019. This represents a significant reduction in the company's leverage or obligations associated with debt and leases over the period.
Shareholders’ equity also demonstrates a declining pattern throughout these years. From $76.59 billion at the end of 2015, it slightly decreases to $76.19 billion in 2016 and continues this downward trend to $58.17 billion by 2019. This consistent reduction indicates possible challenges with retained earnings, equity issuance, or other comprehensive income affecting the equity base.
The invested capital, which encompasses the company's overall capital invested in operations, similarly shows a decreasing trend. Beginning at approximately $127.50 billion in 2015, invested capital reduces each year, culminating at about $80.27 billion in 2019. This decline suggests a potential shrinking scale of invested assets or capital employed, which could relate to asset divestitures, depreciation outpacing capital expenditure, or capital structure adjustments.
- Total reported debt & leases
- Substantial reduction by nearly 46% from 2015 to 2019, indicating active debt repayment or lease obligation reduction.
- Shareholders’ equity
- Gradual decline of roughly 24% over the period, possibly signaling diminished profitability, dividend distribution exceeding earnings, share repurchases, or adverse comprehensive income impacts.
- Invested capital
- Marked decrease of approximately 37%, reflecting either asset shrinkage, depreciation exceeding reinvestment, or strategic restructuring.
In summary, all three key financial measures present downward trends, with debt levels showing the most pronounced reduction, followed by invested capital and shareholders’ equity. The data implies an overall contraction in the scale of the business's financial operations and capitalization, alongside a strategic effort to reduce leverage.
Cost of Capital
Allergan PLC, cost of capital calculations
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Preferred shares, $0.0001 par value per share (book value) | ÷ | = | × | = | |||||||||
| Long-term debt and capital leases, including current portion3 | ÷ | = | × | × (1 – 12.50%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 12.50%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2019-12-31).
1 US$ in thousands
2 Equity. See details »
3 Long-term debt and capital leases, including current portion. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Preferred shares, $0.0001 par value per share (book value) | ÷ | = | × | = | |||||||||
| Long-term debt and capital leases, including current portion3 | ÷ | = | × | × (1 – 12.50%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 12.50%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2018-12-31).
1 US$ in thousands
2 Equity. See details »
3 Long-term debt and capital leases, including current portion. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Preferred shares, $0.0001 par value per share (book value) | ÷ | = | × | = | |||||||||
| Long-term debt and capital leases, including current portion3 | ÷ | = | × | × (1 – 12.50%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 12.50%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2017-12-31).
1 US$ in thousands
2 Equity. See details »
3 Long-term debt and capital leases, including current portion. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Preferred shares, $0.0001 par value per share (book value) | ÷ | = | × | = | |||||||||
| Long-term debt and capital leases, including current portion3 | ÷ | = | × | × (1 – 12.50%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 12.50%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2016-12-31).
1 US$ in thousands
2 Equity. See details »
3 Long-term debt and capital leases, including current portion. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Preferred shares, $0.0001 par value per share (book value) | ÷ | = | × | = | |||||||||
| Long-term debt and capital leases, including current portion3 | ÷ | = | × | × (1 – 12.50%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 12.50%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2015-12-31).
1 US$ in thousands
2 Equity. See details »
3 Long-term debt and capital leases, including current portion. See details »
4 Operating lease liability. See details »
Economic Spread Ratio
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Economic profit1 | ||||||
| Invested capital2 | ||||||
| Performance Ratio | ||||||
| Economic spread ratio3 | ||||||
| Benchmarks | ||||||
| Economic Spread Ratio, Competitors4 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
1 Economic profit. See details »
2 Invested capital. See details »
3 2019 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =
4 Click competitor name to see calculations.
The financial performance, as indicated by economic value added metrics, demonstrates a consistent pattern of negative economic profit over the five-year period. Simultaneously, invested capital exhibits a declining trend. The economic spread ratio, calculated from these figures, reflects the relationship between economic profit and invested capital, and reveals a generally worsening performance over time.
- Economic Profit
- Economic profit consistently registers as a negative value throughout the observed period, ranging from approximately -21.4 million to -28.6 million US dollars in thousands. While the magnitude of the loss fluctuates year-to-year, it does not demonstrate a clear upward trend towards profitability. The lowest value is observed in 2015, with a slight improvement in 2016, followed by a return to higher losses in 2017, and a gradual, but limited, reduction in losses through 2019.
- Invested Capital
- Invested capital shows a consistent downward trend, decreasing from approximately 127.5 million to 80.3 million US dollars in thousands between 2015 and 2019. This represents a substantial reduction in the capital employed by the entity. The rate of decline appears to accelerate over time, with larger decreases observed in later years.
- Economic Spread Ratio
- The economic spread ratio, expressed as a percentage, is consistently negative, indicating that the entity is not generating returns exceeding its cost of capital. The ratio fluctuates between -20.85% and -27.32%. A general worsening trend is apparent, with the ratio becoming more negative over the period, particularly from 2016 to 2019. This suggests that the gap between the return on invested capital and the cost of capital is widening, indicating deteriorating economic performance relative to the capital employed.
In summary, the observed trends suggest a consistent inability to generate economic profit, coupled with a decreasing capital base and a widening negative economic spread. These factors collectively point to a declining economic performance over the analyzed timeframe.
Economic Profit Margin
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Economic profit1 | ||||||
| Net revenues | ||||||
| Add: Increase (decrease) in deferred revenue | ||||||
| Adjusted net revenues | ||||||
| Performance Ratio | ||||||
| Economic profit margin2 | ||||||
| Benchmarks | ||||||
| Economic Profit Margin, Competitors3 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
1 Economic profit. See details »
2 2019 Calculation
Economic profit margin = 100 × Economic profit ÷ Adjusted net revenues
= 100 × ÷ =
3 Click competitor name to see calculations.
The financial performance, as indicated by economic profit and its margin, demonstrates a consistent pattern of negative economic profit over the five-year period. While the magnitude of the economic loss fluctuates, it remains a persistent characteristic. The economic profit margin, calculated as a percentage of adjusted net revenues, reflects this negative economic profit, exhibiting a substantial negative value throughout the observed timeframe.
- Economic Profit
- Economic profit consistently registers as a negative value across all reported years. The largest negative economic profit is observed in 2015, at approximately -28.63 million US dollars. Subsequent years show fluctuations, with 2016 and 2018 exhibiting comparatively lower losses. However, 2017 shows a return to a loss level similar to 2015. 2019 demonstrates a slight improvement, but remains significantly negative at approximately -21.39 million US dollars. Overall, the trend suggests a relatively stable pattern of substantial economic loss, with no indication of achieving positive economic profit.
- Adjusted Net Revenues
- Adjusted net revenues demonstrate a more stable pattern. Revenues initially decrease from 2015 to 2016, then increase through 2017, 2018, and 2019. The highest revenue figure is recorded in 2019, at approximately 16.08 million US dollars. While revenue growth is present, it does not appear to be sufficient to offset the consistently negative economic profit.
- Economic Profit Margin
- The economic profit margin is consistently negative, ranging from -190.04% in 2015 to -133.05% in 2019. A clear downward trend is observed from 2015 to 2016, followed by fluctuations, and then a continued, albeit slower, downward trend through 2019. The magnitude of the negative margin indicates that the cost of capital significantly exceeds the returns generated from adjusted net revenues. The decreasing negative margin in the later years suggests a slight improvement in the relationship between profitability and capital costs, but the margin remains substantially negative.
In summary, the analysis reveals a consistent inability to generate economic profit, despite relatively stable and growing adjusted net revenues. The economic profit margin reinforces this conclusion, demonstrating a substantial and persistent negative return on investment.